Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Aptinyx Stock Sank Today

By Keith Speights - Oct 21, 2020 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted negatively to the company's announcement of a secondary stock offering.

What happened

Shares of Aptinyx ( APTX 0.93% ) were sinking 7.2% lower as of 3:32 p.m. EDT on Wednesday after falling as much as 12.8% earlier in the day. The decline stemmed from the company's announcement on Tuesday evening that it plans to sell 12 million shares in a public stock offering.

So what

Biotech stocks typically drop on news of a secondary stock offering. The issuance of new shares dilutes the value of existing shares.

A one-dollar bill folded into an arrow pointing down.

Image source: Getty Images.

In Aptinyx's case, the sale of 12 million shares represents roughly 25% of the company's outstanding shares. It wouldn't have been surprising if Aptinyx's share price had fallen even more than it actually did with that level of dilution.

The timing for Aptinxy's announcement of a public stock offering was smart, however. On Monday, the company reported positive results from its first phase 2 study evaluating NYX-783 in treating post-traumatic stress disorder (PTSD). Aptinyx's shares soared 55% on the encouraging clinical update

Now what

Aptinyx expects to use the proceeds from its public offering to advance its pipeline candidates. In particular, the company hopes to begin a pivotal study of NYX-783 in treating PTSD next year. It also anticipates resuming the phase 2 study of NYX-2925 in treating diabetic peripheral neuropathy (nerve damage that can be a complication of diabetes) either later this year or in early 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aptinyx Inc. Stock Quote
Aptinyx Inc.
APTX
$2.17 (0.93%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.